PE20241385A1 - Formulaciones de radiprodil - Google Patents

Formulaciones de radiprodil

Info

Publication number
PE20241385A1
PE20241385A1 PE2024000212A PE2024000212A PE20241385A1 PE 20241385 A1 PE20241385 A1 PE 20241385A1 PE 2024000212 A PE2024000212 A PE 2024000212A PE 2024000212 A PE2024000212 A PE 2024000212A PE 20241385 A1 PE20241385 A1 PE 20241385A1
Authority
PE
Peru
Prior art keywords
radiprodil
formulations
compound
formula
pharmaceutically acceptable
Prior art date
Application number
PE2024000212A
Other languages
English (en)
Spanish (es)
Inventor
Marie Genin
Pierandrea Muglia
Original Assignee
Grin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grin Therapeutics Inc filed Critical Grin Therapeutics Inc
Publication of PE20241385A1 publication Critical patent/PE20241385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2024000212A 2021-08-06 2022-08-05 Formulaciones de radiprodil PE20241385A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163230331P 2021-08-06 2021-08-06
PCT/US2022/039543 WO2023014956A1 (en) 2021-08-06 2022-08-05 Formulations of radiprodil

Publications (1)

Publication Number Publication Date
PE20241385A1 true PE20241385A1 (es) 2024-07-09

Family

ID=83189017

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000212A PE20241385A1 (es) 2021-08-06 2022-08-05 Formulaciones de radiprodil

Country Status (12)

Country Link
US (2) US20250127770A1 (cg-RX-API-DMAC7.html)
EP (1) EP4380547A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024529185A (cg-RX-API-DMAC7.html)
KR (1) KR20240052765A (cg-RX-API-DMAC7.html)
CN (1) CN118019521A (cg-RX-API-DMAC7.html)
AU (1) AU2022323381A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228004A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024002715A2 (cg-RX-API-DMAC7.html)
IL (1) IL310652A (cg-RX-API-DMAC7.html)
MX (1) MX2024001744A (cg-RX-API-DMAC7.html)
PE (1) PE20241385A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023014956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024402343A1 (en) 2023-12-20 2026-06-11 Grin Therapeutics, Inc. Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100890676B1 (ko) 2001-07-24 2009-03-26 리히데 게데온 베기에스제티 기아르 알티 신규한 카르복시산 아미드 화합물
EA201170007A1 (ru) * 2008-07-08 2011-08-30 Рихтер Гедеон Нирт. Новая кристаллическая форма 2-[4-(4-фторбензил)пиперидин-1-ил]-2-оксо-n-(2-оксо-2,3-дигидробензоксазол-6-ил)ацетамида
US20100048630A1 (en) * 2008-08-21 2010-02-25 Pradeep Banerjee Methods for treating cns disorders
HUP0900130A3 (en) * 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
US8328687B2 (en) 2010-07-09 2012-12-11 Ford Global Technologies, Llc Method for controlling an engine that may be automatically stopped

Also Published As

Publication number Publication date
KR20240052765A (ko) 2024-04-23
CN118019521A (zh) 2024-05-10
CO2024002715A2 (es) 2024-05-20
IL310652A (en) 2024-04-01
CA3228004A1 (en) 2023-02-09
US20260053786A1 (en) 2026-02-26
JP2024529185A (ja) 2024-08-01
AU2022323381A1 (en) 2024-03-21
WO2023014956A9 (en) 2023-12-14
EP4380547A1 (en) 2024-06-12
MX2024001744A (es) 2024-04-23
WO2023014956A1 (en) 2023-02-09
US20250127770A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
ECSP078023A (es) Ingrediente farmacéutico activo en base a canabinoide
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
CY1119357T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν συνδετες υποδοχεων σιγμα
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
MX2024014628A (es) Compuesto para inhibir o degradar bcl6 y uso de este en farmacia
CL2022001337A1 (es) Derivados de piridopirimidinona como antagonistas de ahr
CR20180580A (es) Piridinas sustituidas como inhibidores de dnmt1
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
BR112023026909A2 (pt) Sal farmaceuticamente aceitável de ap1189 ((e)-n-[1-(2-nitrofenil)-1-h-pirrol-2-il-alilidenoamino]-guanidina), composição farmacêutica, forma de dosagem única, e, formulação oral
BR112022007207A2 (pt) Composição farmacêutica que compreende selexipag
AR133241A1 (es) Compuestos, composiciones y métodos
AR074309A1 (es) Compuestos anti-inflamatorios y sus composiciones farmaceuticas, dentifricas y adhesivas. metodo
WO2021076938A8 (en) Tropolone derivatives and tautomers thereof for iron regulation in animals
AR132166A1 (es) Inhibidores de inflamasoma nlrp3 y usos de los mismos
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
MX2022001429A (es) Formulaciones que incluyen dihidrohonokiol.
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
CL2022001317A1 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma.
MX2022002022A (es) Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones.
CL2025001309A1 (es) Formulaciones orales compactables de ibutamoren
CL2021001621A1 (es) Formulaciones orales de branaplam
GT201000064A (es) Formulaciones galénicas de alisquireno